Loading…
AMRX
Amneal Pharmaceuticals, Inc.
NASDAQ· Healthcare· Drug Manufacturers - Specialty & Generic· CUSIP 03168L105
$20.48+1.39%Price as of Oct 23, 00:49 UTC · updated once a day, after the close
At a glance
Amneal Pharmaceuticals, Inc. (AMRX) is listed on NASDAQ and classified in Drug Manufacturers - Specialty & Generic, part of the Healthcare sector. It is headquartered in Bridgewater, United States and has 8,700 employees. The company is worth $7.13B and trades at 41.0x its earnings of the last twelve months; the median for its sector is 24.3x. Revenue was $3.02B in fiscal 2025, up 8.0% from the year before. Net income was $72.06M. The share price is 3.3% below its 52-week high of $21.18. 5 of the 38 superinvestors we track held it at the end of Q2 2026. The largest position belongs to Ken Griffin (Citadel Advisors), at $19.36M. In that quarter, 1 of them opened or added to the position and 3 reduced it. No open-market insider trades in it were filed over the last 30 days.
Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.
Key metrics
- Market cap
- $7.13B
- P/E
- 41.0x
- Forward P/E
- 17.0x
- P/B
- 198.8x
- Dividend yield
- 0.00%
- Payout
- —
- EPS
- $0.50
- ROE
- 613.02%
- Profit margin
- 5.05%
- Revenue growth
- +9.90%
- Beta
- 1.22
- 52-week high
- $21.18
- 52-week low
- $9.99
History
Year by year, from the annual reports; dividends from the payments themselves.
Bars are year-end balances; lines are what happened during the year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▲ +358.9% over 5Y.
today you would have $3,493.62▲ +249.4%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 8 closed years, each at that year’s closing price and reported numbers.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $12.60 | $7.92 | $6.07 | $1.99 | $4.79 | $4.57 | $4.82 | $13.53 | |
| P/E | 57.3x | 57.3x | — | — | — | 68.4x | 7.5x | — | — |
| P/S | 0.6x | 1.3x | 0.9x | 0.8x | 0.1x | 0.3x | 0.3x |
Fair price, seven ways
Seven formulas applied to the reported numbers, each with its assumption next to the result. None of them predicts a price.
Earnings
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Earnings
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Earnings
$12.14
Median P/E of 24.3 among peers in the sector.
Earnings
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Cash flow
$6.79
Cash flow growing 5.0% a year for 10 years, discounted at 10%, then 2.5% forever.
Operating
$12.90
Sector median of 14.1x operating profit, less net debt. Banks have no EBITDA.
Dividends
—
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| PRAXPraxis Precision Medicines, Inc. | $258.92 | — | 5.4x | 0.00% | -38.86% | $7.23B |
| IONSIonis Pharmaceuticals Inc | $43.91 | — | 16.5x | 0.00% | -105.50% | $7.3B |
| ALKSAlkermes plc. | $44.18 | 113.3x | 4.1x | 0.00% | 3.85% | $7.41B |
| SYRESpyre Therapeutics, Inc. | $79.90 |
About the company
- 8,700
- Bridgewater, United States